Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
Deep-pocketed investors have adopted a bearish approach towards Moderna (NASDAQ:MRNA), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in MRNA usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 16 extraordinary options activities for Moderna. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 25% leaning bullish and 68% bearish. Among these notable options, 12 are puts, totaling $875,364, and 4 are calls, amounting to $237,304.
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $85.0 and $130.0 for Moderna, spanning the last three months.
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Moderna's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Moderna's significant trades, within a strike price range of $85.0 to $130.0, over the past month.
Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
---|---|---|---|---|---|---|---|---|---|---|---|
MRNA | PUT | TRADE | BULLISH | 06/20/25 | $17.6 | $14.9 | $15.9 | $85.00 | $318.0K | 447 | 200 |
MRNA | PUT | SWEEP | BEARISH | 01/17/25 | $26.35 | $26.25 | $26.3 | $105.00 | $126.2K | 18.8K | 72 |
MRNA | PUT | SWEEP | BULLISH | 10/18/24 | $7.7 | $7.55 | $7.7 | $85.00 | $92.4K | 998 | 151 |
MRNA | CALL | SWEEP | BEARISH | 09/20/24 | $2.86 | $2.85 | $2.85 | $90.00 | $74.4K | 1.2K | 628 |
MRNA | CALL | SWEEP | BEARISH | 12/18/26 | $18.0 | $17.65 | $17.65 | $125.00 | $65.3K | 108 | 39 |
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 39 mRNA development candidates in clinical trials as of mid-2023. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
In light of the recent options history for Moderna, it's now appropriate to focus on the company itself. We aim to explore its current performance.
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $121.4.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Moderna, Benzinga Pro gives you real-time options trades alerts.
Posted In: MRNA